Thank you for correcting the text in this article. Your corrections improve Papers Past searches for everyone. See the latest corrections.

This article contains searchable text which was automatically generated and may contain errors. Join the community and correct any errors you spot to help us improve Papers Past.

Article image
Article image
Article image
Article image
Article image
Article image
Article image
Article image
Article image
Article image

Eleven receive A.I.D.S. drug

PA Wellington Eleven patients in New Zealand are now receiving tbe expensive A.I.D.S. drug, AZT, says the Health Department’s manager of medicines and benefits, Dr Ralph Riseley. The drug cost $16,000 for each patient for a year’s supply, according to the A.LD.S. Advisory Council chairman, Dr Richard Meech, and that price did not include hidden costs of follow-up checks and laboratory tests. Meech said the drug

was available only to patients with diagnosed or suspected pneumocystis pneumonia — a kind of pneumonia that is usually rare, but common in people with their immunity reduced by the A.I.D.S. virus.

AZT stands for azidothymldine, although it is also called zidovudine, and marketed under the name, Retrovir.

It is the only drug found so far to slow the spread of the virus through a patient’s immune system, although its makers Wellcome have said the drug cure < tl f

Permanent link to this item

https://paperspast.natlib.govt.nz/newspapers/CHP19871130.2.138.21

Bibliographic details

Press, 30 November 1987, Page 32

Word Count
148

Eleven receive A.I.D.S. drug Press, 30 November 1987, Page 32

Eleven receive A.I.D.S. drug Press, 30 November 1987, Page 32

Help

Log in or create a Papers Past website account

Use your Papers Past website account to correct newspaper text.

By creating and using this account you agree to our terms of use.

Log in with RealMe®

If you’ve used a RealMe login somewhere else, you can use it here too. If you don’t already have a username and password, just click Log in and you can choose to create one.


Log in again to continue your work

Your session has expired.

Log in again with RealMe®


Alert